Leukemia
Conditions
Keywords
recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, acute undifferentiated leukemia, adult acute minimally differentiated myeloid leukemia (M0), childhood acute minimally differentiated myeloid leukemia (M0), adult acute myeloblastic leukemia without maturation (M1), childhood acute myeloblastic leukemia without maturation (M1), adult acute myeloblastic leukemia with maturation (M2), childhood acute myeloblastic leukemia with maturation (M2), adult acute myelomonocytic leukemia (M4), childhood acute myelomonocytic leukemia (M4), adult acute monoblastic leukemia (M5a), childhood acute monoblastic leukemia (M5a), adult acute monocytic leukemia (M5b), childhood acute monocytic leukemia (M5b), adult erythroleukemia (M6a), adult pure erythroid leukemia (M6b), childhood acute erythroleukemia (M6), adult acute megakaryoblastic leukemia (M7), childhood acute megakaryocytic leukemia (M7), recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia
Brief summary
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of clofarabine when given together with cytarabine and to see how well they work in treating young patients with refractory or relapsed acute myeloid leukemia or acute lymphoblastic leukemia. (Phase I closed to enrollment as of 09/16/09)
Detailed description
OBJECTIVES: Primary * To define the overall response rate (complete remission or remission without platelet recovery) in young patients with relapsed or refractory acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) treated with clofarabine in combination with cytarabine. Secondary * To determine the safety profile and tolerability of clofarabine when given in combination with cytarabine in patients with and without prior stem cell transplantation. * To identify apoptosis specific genes that are important in mediating response to clofarabine and cytarabine. * To quantitate the level of human equilibrative nucleoside transporter proteins (hENT1 and hENT2) and human concentrative nucleoside transporter proteins (hCNT2 and hCNT3) in blasts of these patients. * To determine gene expression profiles at study entry and at time of relapse in order to isolate profiles that may predict response and also to complement apoptosis specific protein arrays. * To perform serial measurements of minimal residual disease (MRD) to provide an objective determination of the effectiveness of this treatment regimen and to correlate with post remission events (relapse, death). * To perform FLT3/ITD analysis to help determine the prevalence and clinical significance of this somatic mutation in patients with relapsed AML. OUTLINE: This is a multicenter, phase I, dose-escalation study of clofarabine followed by a phase II study. Patients are stratified according to disease (acute lymphoblastic leukemia \[ALL\] vs acute myeloid leukemia \[AML\]). (Phase I closed to accrual as of 09/16/09) * Intrathecal CNS prophylaxis (all patients with ALL and at physician's discretion for patients with AML or acute leukemia of ambiguous lineage): Patients receive intrathecal (IT) cytarabine on day 0 of the first course of induction therapy. Patients also receive IT methotrexate on day 1 of the second course of induction therapy and on day 1 of all courses of maintenance therapy. * Induction therapy: * Course 1: Patients receive cytarabine IV over 2 hours and clofarabine IV over 2 hours on days 1-5. Patients with ≥ 5% blasts (i.e., M2 or M3 bone marrow) at days 14-21 proceed immediately to course 2 of induction therapy. Patients with \< 5% blasts (i.e., M1 bone marrow) may proceed to course 2 of induction therapy at blood count recovery or at day 42. * Course 2: Patients receive clofarabine IV over 2 hours followed by cytarabine IV over 2 hours on days 1-5. After the second course of induction therapy, patients with M2 or M3 bone marrow at days 14-21 are removed from the study. Patients with M1 bone marrow proceed to maintenance therapy 14-42 days after the initiation of course 2. * Maintenance therapy: Patients receive clofarabine and cytarabine as in induction therapy. Treatment repeats every 14-42 days for up to 10 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo blood and bone marrow sample collection periodically for correlative laboratory studies. After completion of study therapy, patients are followed periodically for up to 5 years. PROJECTED ACCRUAL: A total of 87 patients will be accrued for this study.
Interventions
DRUGclofarabine
Given IV for 5 days
DRUGcytarabine
Given IV
DRUGmethotrexate
Given intrathecally or IT age based dosage
OTHERlaboratory biomarker analysis
Sponsors
National Cancer Institute (NCI)
Children's Oncology Group
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of 1 of the following: * Acute myeloid leukemia (AML) with ≥ 5% blasts in the bone marrow (M2/M3 bone marrow) with or without extramedullary disease * Acute lymphoblastic leukemia (ALL) with \> 25% blasts in the bone marrow (M3 bone marrow) with or without extramedullary disease * Acute leukemia of ambiguous lineage with ≥ 5% blasts in the bone marrow (M2/M3 bone marrow) with or without extramedullary disease * Disease must have relapsed after or be refractory to prior induction therapy * Patients with AML or acute leukemia of ambiguous lineage must be in first relapse OR refractory to first induction therapy with ≤ 1 attempt at remission induction * Patients with AML who enroll on the phase I portion of the study must have received prior mitoxantrone hydrochloride and cytarabine for newly diagnosed AML (phase I closed to accrual as of 09/16/09) * Patients with ALL must be in second or third relapse (≤ 3 prior induction regimens) OR refractory to reinduction in first relapse * Patients with ALL refractory to first induction therapy are not eligible * No acute promyelocytic leukemia * No CNS 3 involvement (i.e., WBC ≥ 5/μL in the cerebrospinal fluid with blasts present on cytospin) PATIENT CHARACTERISTICS: * Karnofsky performance status (PS) 50-100% (\> 16 years of age) OR Lansky PS 50-100% (≤ 16 years of age) OR ECOG PS 0-2 * Life expectancy ≥ 8 weeks * Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min * Direct bilirubin ≤ 1.5 times upper limit of normal (ULN) * ALT \< 2.5 times ULN (unless it is related to leukemic involvement) * Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 45% by gated radionuclide study * No evidence of dyspnea at rest or exercise intolerance * Pulse oximetry \> 94% at room air * Amylase ≤ 1.5 times ULN * Lipase \< 1.5 times ULN * No active, uncontrolled grade 3 or 4 infection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment * No known hepatitis B or C infection or history of cirrhosis PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Recovered from all prior therapy\* * At least 14 days since prior cytotoxic therapy (except hydroxyurea and intrathecal chemotherapy)\* * At least 7 days since prior biologic agent\* * At least 14 days since prior monoclonal antibody therapy\* * No more than 1 prior autologous or allogeneic hematopoietic stem cell transplantation * No evidence of active graft-vs-host disease * At least 4 months since transplantation * No other concurrent chemotherapy or immunomodulating agents * No other concurrent investigational therapy NOTE: \*Patients who relapse during ALL maintenance therapy do not require a waiting period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response (CR for ALL Patients), (CR + CRp for AML Patients) | 2 cycles or up to 84 days | Overall response for ALL patients: CR - complete remission (attainment of an M1 bone marrow (\< 5% blasts) with no evidence of circulating blasts or extramedullary disease and with recovery of peripheral counts (absolute neutrophil count (ANC) \> 750/μL and platelet count \> 75,000/μL). Overall response for AML patients: (CR + CRp), defined as: CR - complete remission (attainment of an M1 bone marrow (\<5% blasts) with no evidence of circulating blasts or extramedullary disease and with recovery of peripheral blood counts (absolute neutrophil count (ANC) \> 1000/uL and platelet count \> 100,000/uL)) or CRp - remission without platelet recovery (Attainment of an M1 bone marrow (\<5% blasts) with no evidence of circulating blasts or extramedullary disease and with recovery of absolute neutrophil count (ANC) \> 1000/uL and platelet transfusion independence (defined as: no platelet transfusions x 1 week)). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Tolerability as Measured by CTCAE v3.0 | End of therapy | Number of participants with at least one grade 3 or higher adverse event during therapy. |
| Correlate the Expression of Apoptosis Specific Genes | End of therapy | Correlate the expression of apoptosis specific genes with chemoresistance and determine whether therapy with clofarabine is able to overcome blocks in apoptosis through modulation of gene expression. Gene expression analysis will be performed on specimens obtained during therapy. Apoptosis specific microarray data will be analyzed using GeneTraffic software (Iobion Informatics, La Jolla CA). |
Countries
Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients. Clofarabine 40 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
clofarabine: Given IV for 5 days
cytarabine: Given IV
methotrexate: Given intrathecally or IT age based dosage
laboratory biomarker analysis | 8 |
| Clofarabine 40 mg/m² to Assess Feasibility in AML Patients. Clofarabine 40 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
clofarabine: Given IV for 5 days
cytarabine: Given IV
methotrexate: Given intrathecally or IT age based dosage
laboratory biomarker analysis | 2 |
| Clofarabine 52 mg/m² to Assess Feasibility in ALL Patients. Clofarabine 52 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
clofarabine: Given IV for 5 days
cytarabine: Given IV
methotrexate: Given intrathecally or IT age based dosage
laboratory biomarker analysis | 3 |
| Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients. Clofarabine 52 mg/m² to assess efficacy in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
clofarabine: Given IV for 5 days
cytarabine: Given IV
methotrexate: Given intrathecally or IT age based dosage
laboratory biomarker analysis | 10 |
| Clofarabine 52 mg/m² to Assess Feasibility in AML Patients. Clofarabine 52 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
clofarabine: Given IV for 5 days
cytarabine: Given IV
methotrexate: Given intrathecally or IT age based dosage
laboratory biomarker analysis | 7 |
| Clofarabine 52 mg/m² to Assess Efficacy in AML Patients Clofarabine 52 mg/m² to assess efficacy in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
clofarabine: Given IV for 5 days
cytarabine: Given IV
methotrexate: Given intrathecally or IT age based dosage
laboratory biomarker analysis | 42 |
| Clofarabine 52 mg/m² to Assess Efficacy - Ambiguous Lineage pt Clofarabine 52 mg/m² to assess efficacy in acute leukemia of ambiguous lineage patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
clofarabine: Given IV for 5 days
cytarabine: Given IV
methotrexate: Given intrathecally or IT age based dosage
laboratory biomarker analysis | 2 |
| Total | 74 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 |
|---|---|---|---|---|---|---|---|---|
| Overall Study | Ineligible | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Overall Study | Inevaluable | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | Clofarabine 40 mg/m² to Assess Feasibility in AML Patients. | Clofarabine 52 mg/m² to Assess Feasibility in ALL Patients. | Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients. | Clofarabine 52 mg/m² to Assess Feasibility in AML Patients. | Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients. | Clofarabine 52 mg/m² to Assess Efficacy in AML Patients | Clofarabine 52 mg/m² to Assess Efficacy - Ambiguous Lineage pt | Total |
|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 1 Participants | 3 Participants | 9 Participants | 7 Participants | 7 Participants | 34 Participants | 1 Participants | 62 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 8 Participants | 1 Participants | 12 Participants |
| Age, Continuous | 15.09 years STANDARD_DEVIATION 6.33 | 13.09 years STANDARD_DEVIATION 1.54 | 9.16 years STANDARD_DEVIATION 6.69 | 9.01 years STANDARD_DEVIATION 5.79 | 12.75 years STANDARD_DEVIATION 6.37 | 12.01 years STANDARD_DEVIATION 7.12 | 19.65 years STANDARD_DEVIATION 1.8 | 15.13 years STANDARD_DEVIATION 5.94 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 2 Participants | 1 Participants | 0 Participants | 1 Participants | 7 Participants | 0 Participants | 11 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 2 Participants | 0 Participants | 8 Participants | 6 Participants | 6 Participants | 35 Participants | 2 Participants | 59 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 8 Participants | 0 Participants | 11 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 4 Participants | 0 Participants | 6 Participants |
| Race (NIH/OMB) White | 1 Participants | 2 Participants | 8 Participants | 7 Participants | 6 Participants | 28 Participants | 2 Participants | 54 Participants |
| Region of Enrollment Canada | 1 participants | 0 participants | 2 participants | 0 participants | 1 participants | 5 participants | 0 participants | 9 participants |
| Region of Enrollment United States | 1 participants | 3 participants | 8 participants | 7 participants | 7 participants | 37 participants | 2 participants | 65 participants |
| Sex: Female, Male Female | 0 Participants | 2 Participants | 4 Participants | 3 Participants | 5 Participants | 20 Participants | 1 Participants | 35 Participants |
| Sex: Female, Male Male | 2 Participants | 1 Participants | 6 Participants | 4 Participants | 3 Participants | 22 Participants | 1 Participants | 39 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk |
|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 8 / 8 | 2 / 2 | 3 / 3 | 10 / 10 | 7 / 7 | 38 / 40 | 2 / 2 |
| serious Total, serious adverse events | 5 / 8 | 2 / 2 | 2 / 3 | 7 / 10 | 3 / 7 | 14 / 40 | 2 / 2 |
Outcome results
Primary
Overall Response (CR for ALL Patients), (CR + CRp for AML Patients)
Overall response for ALL patients: CR - complete remission (attainment of an M1 bone marrow (\< 5% blasts) with no evidence of circulating blasts or extramedullary disease and with recovery of peripheral counts (absolute neutrophil count (ANC) \> 750/μL and platelet count \> 75,000/μL). Overall response for AML patients: (CR + CRp), defined as: CR - complete remission (attainment of an M1 bone marrow (\<5% blasts) with no evidence of circulating blasts or extramedullary disease and with recovery of peripheral blood counts (absolute neutrophil count (ANC) \> 1000/uL and platelet count \> 100,000/uL)) or CRp - remission without platelet recovery (Attainment of an M1 bone marrow (\<5% blasts) with no evidence of circulating blasts or extramedullary disease and with recovery of absolute neutrophil count (ANC) \> 1000/uL and platelet transfusion independence (defined as: no platelet transfusions x 1 week)).
Time frame: 2 cycles or up to 84 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients. | Overall Response (CR for ALL Patients), (CR + CRp for AML Patients) | 1 participants |
| Clofarabine 40 mg/m² to Assess Feasibility in AML Patients. | Overall Response (CR for ALL Patients), (CR + CRp for AML Patients) | 2 participants |
| Clofarabine 52 mg/m² to Assess Feasibility in ALL Patients. | Overall Response (CR for ALL Patients), (CR + CRp for AML Patients) | 0 participants |
| Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients. | Overall Response (CR for ALL Patients), (CR + CRp for AML Patients) | 2 participants |
| Clofarabine 52 mg/m² to Assess Feasibility in AML Patients. | Overall Response (CR for ALL Patients), (CR + CRp for AML Patients) | 2 participants |
| Clofarabine 52 mg/m² to Assess Efficacy in AML Patients | Overall Response (CR for ALL Patients), (CR + CRp for AML Patients) | 19 participants |
| Clofarabine 52 mg/m² to Assess Efficacy - Ambiguous Lineage pt | Overall Response (CR for ALL Patients), (CR + CRp for AML Patients) | 2 participants |
Secondary
Correlate the Expression of Apoptosis Specific Genes
Correlate the expression of apoptosis specific genes with chemoresistance and determine whether therapy with clofarabine is able to overcome blocks in apoptosis through modulation of gene expression. Gene expression analysis will be performed on specimens obtained during therapy. Apoptosis specific microarray data will be analyzed using GeneTraffic software (Iobion Informatics, La Jolla CA).
Time frame: End of therapy
Population: The analysis was not completed, because the tissue microarray was unsuccessful.
Secondary
Safety and Tolerability as Measured by CTCAE v3.0
Number of participants with at least one grade 3 or higher adverse event during therapy.
Time frame: End of therapy
Population: Ineligible (n=2) and inevaluable (n=1) patients are excluded
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients. | Safety and Tolerability as Measured by CTCAE v3.0 | 7 number participants |
| Clofarabine 40 mg/m² to Assess Feasibility in AML Patients. | Safety and Tolerability as Measured by CTCAE v3.0 | 2 number participants |
| Clofarabine 52 mg/m² to Assess Feasibility in ALL Patients. | Safety and Tolerability as Measured by CTCAE v3.0 | 3 number participants |
| Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients. | Safety and Tolerability as Measured by CTCAE v3.0 | 10 number participants |
| Clofarabine 52 mg/m² to Assess Feasibility in AML Patients. | Safety and Tolerability as Measured by CTCAE v3.0 | 7 number participants |
| Clofarabine 52 mg/m² to Assess Efficacy in AML Patients | Safety and Tolerability as Measured by CTCAE v3.0 | 35 number participants |
| Clofarabine 52 mg/m² to Assess Efficacy - Ambiguous Lineage pt | Safety and Tolerability as Measured by CTCAE v3.0 | 2 number participants |